Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11433072 Oral dosage forms of ibrutinib

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Date Filed
June 10, 2021
0
Date of Patent
September 6, 2022
0
Patent Application Number
17343900
0
Patent Citations
‌
US Patent 10961251 Crystalline forms of a Bruton's tyrosine kinase inhibitor
‌
US Patent 10752634 Crystalline forms of a brutons tyrosine kinase inhibitor
‌
US Patent 10004746 Use of inhibitors of Bruton's tyrosine kinase (Btk)
‌
US Patent 10016435 Use of inhibitors of Bruton's tyrosine kinase (Btk)
0
‌
US Patent 10106548 Crystalline forms of a Bruton's tyrosine kinase inhibitor
‌
US Patent 10125140 Crystalline forms of a bruton's tyrosine kinase inhibitor
0
‌
US Patent 10294231 Crystalline forms of a Bruton's tyrosine kinase inhibitor
‌
US Patent 10294232 Crystalline forms of a Bruton's tyrosine kinase inhibitor
‌
US Patent 10478439 Use of inhibitors of bruton's tyrosine kinase (Btk)
‌
US Patent 10463668 Methods of treating and preventing graft versus host disease
•••
Patent Inventor Names
Ahmad Arif Mohammad
0
Mahmoud Ghannam
0
Mohammad Al Hreebat
0
Shahin Fesharaki
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
11433072
0
Patent Primary Examiner
‌
Jessica Worsham
0

Find more entities like US Patent 11433072 Oral dosage forms of ibrutinib

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo